These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 19117966)

  • 1. Comparison of immunogenic potentials of bovine thrombin preparations.
    Zhu H; Hoppensteadt D; Adiguzel C; Bick RL; Fareed J
    Clin Appl Thromb Hemost; 2009 Feb; 15(1):41-9. PubMed ID: 19117966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-reactivity of rabbit anti-bovine prothrombin/thrombin IgGs with bovine factor V/Va-related antigens.
    He Zhu ; Hoppensteadt D; Morris M; Fareed J
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):522-8. PubMed ID: 20699260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced immunogenic potential of membrane filtered bovine thrombin preparations for hemostatic application.
    Zhu H; Hoppensteadt D; Wahi R; Cunanan J; Adiguzel C; Bick RL; Fareed J
    Clin Appl Thromb Hemost; 2009 Feb; 15(1):32-40. PubMed ID: 18977777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative purity of different bovine thrombin preparations.
    Zhu H; Hoppensteadt D; Iqbal O; Litinas E; Adiguzel C; Fareed J
    Clin Appl Thromb Hemost; 2009 Dec; 15(6):681-8. PubMed ID: 19850589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further removal of factor v related antigen from bovine thrombin by utilizing a membrane-filtration step.
    Terrab A; Pawlak D; Spaay P; Hoppensteadt D; Fareed J
    Clin Appl Thromb Hemost; 2008 Apr; 14(2):135-40. PubMed ID: 18160573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-reactivity of rabbit anti-bovine thrombin IgGs with human alpha-thrombin and a recombinant version of human thrombin (Recothrom).
    He Zhu ; Hoppensteadt D; Cunanan J; Fareed J
    Clin Appl Thromb Hemost; 2010 Jun; 16(3):273-80. PubMed ID: 20547555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-reactivity of various thrombin products with anti-rabbit antibodies to bovine, human, and recombinant thrombin.
    Sadeghi N; Zhu H; Setty SK; Cunanan J; Hoppensteadt D; Fareed J
    Clin Appl Thromb Hemost; 2012 Jun; 18(3):243-8. PubMed ID: 22345489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative purity of thrombin-based hemostatic agents used in surgery.
    Schoenecker JG; Johnson RK; Fields RC; Lesher AP; Domzalski T; Baig K; Lawson JH; Parker W
    J Am Coll Surg; 2003 Oct; 197(4):580-90. PubMed ID: 14522327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors.
    Berruyer M; Amiral J; Ffrench P; Belleville J; Bastien O; Clerc J; Kassir A; Estanove S; Dechavanne M
    J Thorac Cardiovasc Surg; 1993 May; 105(5):892-7. PubMed ID: 8487567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function.
    Chouhan VD; De La Cadena RA; Nagaswami C; Weisel JW; Kajani M; Rao AK
    Thromb Haemost; 1997 Feb; 77(2):343-9. PubMed ID: 9157594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk and clinical significance of developing antibodies induced by topical thrombin preparations.
    Dorion RP; Hamati HF; Landis B; Frey C; Heydt D; Carey D
    Arch Pathol Lab Med; 1998 Oct; 122(10):887-94. PubMed ID: 9786349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the esterase (TAMe) and clotting activities of human and bovine thrombin preparations.
    Lanchantin GF; Presant CA; Hart DW; Friedmann JA
    Thromb Diath Haemorrh; 1965 Sep; 14(1-2):159-75. PubMed ID: 16955973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in topical thrombins.
    Kessler CM; Ortel TL
    Thromb Haemost; 2009 Jul; 102(1):15-24. PubMed ID: 19572062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihuman factor V antibodies after use of relatively pure bovine thrombin.
    Lawson JH; Lynn KA; Vanmatre RM; Domzalski T; Klemp KF; Ortel TL; Niklason LE; Parker W
    Ann Thorac Surg; 2005 Mar; 79(3):1037-8. PubMed ID: 15734434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma.
    Nelson PA; Powers JN; Estridge TD; Elder EA; Alea AD; Sidhu PK; Sehl LC; DeLustro FA
    J Biomed Mater Res; 2001; 58(6):710-9. PubMed ID: 11745525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-mediated coagulopathy: a case report.
    Naoum JJ
    Pharmacotherapy; 2009 Jul; 29(7 Pt 2):13S-7S. PubMed ID: 19558280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter pilot study to estimate the prevalence of bovine and human coagulation antibodies in the general US population.
    Fareed J; Paterson CA; Crean SM
    Clin Appl Thromb Hemost; 2011 Apr; 17(2):164-70. PubMed ID: 21078614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of recombinant human thrombin and plasma-derived human alpha-thrombin.
    Bishop PD; Lewis KB; Schultz J; Walker KM
    Semin Thromb Hemost; 2006 Apr; 32 Suppl 1():86-97. PubMed ID: 16673270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation.
    Jeimy SB; Fuller N; Tasneem S; Segers K; Stafford AR; Weitz JI; Camire RM; Nicolaes GA; Hayward CP
    Thromb Haemost; 2008 Dec; 100(6):1058-67. PubMed ID: 19132231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure.
    Savage WJ; Kickler TS; Takemoto CM
    Pediatr Blood Cancer; 2007 Dec; 49(7):1025-9. PubMed ID: 16526049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.